Clinical trials in diffuse large B cell lymphoma

The list below shows The Lymphoma Group's current clinical trials open/due to open for recruitment for Diffuse large B-cell lymphoma patients.

If you would like to know how to access our trials, please see how to contact us.

  • GEN3013 - Phase 1/2 study using antibody GEN3013 to target CD20- expressing cells in patients with B cell non Hodgkin lymphoma

    Suitable for patients with B cell non-Hodgkin lymphoma which has come back after previous treatment

  • JCAR017 - Phase 2 study determining efficacy and safety of JCAR017

    Suitable for patients with lymphoma which has come back after previous treatment

     
  • GO29781 - A phase 1/1b trial testing mosunetuzumab, on its own or with atezolizumab

    Suitable for patients with lymphoma which has come back after previous treatment


  • GCT3013-02 - A phase 1b/2 trial of a targeted treatment, epcoritamab, in combination with different chemotherapy regimens, in people with B-cell non-Hodgkin lymphoma.


  • LOTIS-3 - A phase 1/2 trial of loncastuximab tesirine and ibrutinib in people with relapsed or refractory diffuse large B-cell lymphoma or mantle cell lymphoma.

 

With special thanks to the following:

Lymphoma actionCRUKBloodwiseNCRI

Last updated: March 2023